Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Recordati Industria Chimica e Farmaceutica SpA
EPS (Diluted)
Recordati Industria Chimica e Farmaceutica SpA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
EPS (Diluted)
€2
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
EPS (Diluted)
-€1
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Friulchem SpA
MIL:FCM
|
EPS (Diluted)
€0
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
EPS (Diluted)
€0
|
CAGR 3-Years
14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Recordati Industria Chimica e Farmaceutica SpA
Glance View
Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.
See Also
What is Recordati Industria Chimica e Farmaceutica SpA's EPS (Diluted)?
EPS (Diluted)
2.1
EUR
Based on the financial report for Sep 30, 2024, Recordati Industria Chimica e Farmaceutica SpA's EPS (Diluted) amounts to 2.1 EUR.
What is Recordati Industria Chimica e Farmaceutica SpA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
11%
Over the last year, the EPS (Diluted) growth was 13%. The average annual EPS (Diluted) growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 4% over the past three years , 5% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet